Given the connection between pain sensitivity, inflammation, and cognitive decline, multidomain interventions personalized by genetic (e.g., SCN9A, COMT polymorphisms), biomarker, and neuroimaging data may represent the most effective paradigm for protecting vulnerable individuals from progressive neurodegeneration [55,56]. This evidence concerns the gene SCN9A and Mental deterioration.